国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語(yǔ)Fran?ais
China
Home / China / Health

Ovarian cancer forum held in Beijing

By Zhou Wenting in Shanghai | chinadaily.com.cn | Updated: 2023-05-08 16:07
Share
Share - WeChat
Experts discuss long-term survival of ovarian cancer patients at a forum on Monday, the 11th World Ovarian Cancer Day. [Photo provided to chinadaily.com.cn]

Helping ovarian cancer patients attain high-quality, long-term survival is now the key focus of medical treatments of the disease, said experts at a forum held in Beijing on Monday, which marked the 11th World Ovarian Cancer Day.

During the forum, doctors shared their latest views and medical practices while patients and their families shared their personal experiences.

The event was jointly hosted by the Beijing Bethune Charitable Foundation and the Health App of People's Daily, and supported by the foundation and Zailab, a domestic innovative biopharmaceutical company.

Di Wen, president of the obstetricians and gynecologists branch of the Chinese Medical Doctor Association and director of the obstetrics and gynecology department of Shanghai Renji Hospital, said that ovarian cancer has a hidden onset and there are no typical symptoms in early stages.

However, experts have reached a consensus that the treatment of ovarian cancer has entered an era of chronic disease management, and doctors and patients should consider recurrent ovarian cancer as a chronic disease.

Prolonging the interval between the completion of chemotherapy and a recurrence or disease progression is currently the main approach to improving the prognosis of patients with recurrent ovarian cancer, said experts.

"The use of PARP inhibitor as maintenance treatment is aimed at prolonging the interval and enhancing the effectiveness of relapse treatment, which would improve the survival of ovarian cancer patients. In this way, it will be no longer difficult to achieve a five-year survival for many patients," said Wu Ming, a chief physician at the gynecological oncology center of the Peking Union Medical College Hospital.

With the application of personalized and precise medical treatment methods, including gene testing, the treatment level of ovarian cancer in China is now on par with that in the West, said Zhang Shiqian, a chief physician at the obstetrics and gynecology department of Qilu Hospital of Shandong University.

"The five-year survival rate among patients has improved these years, and so has the recurrence rate," said Zhang, who is also chairman of the ovarian cancer committee of integrated traditional Chinese and western medicine affiliated with the China Anti-Cancer Association.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
刚察县| 岱山县| 陆良县| 富蕴县| 新营市| 蒲城县| 威信县| 南召县| 台州市| 佛学| 曲靖市| 商城县| 舟山市| 皮山县| 盐边县| 淮安市| 竹北市| 邹平县| 永济市| 息烽县| 江西省| 裕民县| 连城县| 宽甸| 柘荣县| 图木舒克市| 讷河市| 广南县| 二连浩特市| 定兴县| 宁阳县| 定西市| 和龙市| 汕尾市| 三河市| 柘荣县| 眉山市| 高台县| 东光县| 玉环县| 博爱县|